Prostate Cancer Pipeline to Witness Massive Growth as 140+ Pharma Companies Advance 150+ Novel Therapies, Finds DelveInsight | Janssen, Pfizer, Astellas Pharma, Regeneron Pharmaceuticals, Merck, Novartis

DelveInsight's "Prostate Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 140+ companies developing several pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Prostate Cancer treatment landscape. Learn more about the evolving Prostate Cancer pipeline today @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Prostate Cancer Pipeline Report

• In April 2026, FDA Fast Track Designation was granted to SYNC-T SV-102 to expedite treatment for metastatic cases.
• In January 2026, progress in the clinical landscape was noted with therapies like NUBEQA and XTANDI receiving new approvals or showing positive trial results.
• In November 2025, the FDA granted Fast Track Designation to BXCL701 for the treatment of metastatic prostate cancer.
• Prostate cancer originates in the male prostate gland due to DNA mutations and is often diagnosed through PSA testing, imaging, and biopsies once symptoms like urinary difficulty arise.
• DelveInsight's Prostate Cancer Pipeline Insight report identifies a robust clinical development space with 140+ active players advancing 150+ pipeline therapies for treatment across multiple stages, from discovery through Phase III.
• Key pharmaceutical companies leading the Prostate Cancer pipeline include Janssen Research & Development, Pfizer, Astellas Pharma, and Regeneron Pharmaceuticals.
• Novel therapies being explored include antibody-drug conjugates like Ladiratuzumab vedotin and FOR46, which aim to deliver potent payloads directly to cancer cells.
• The report covers various molecule types including monoclonal antibodies, gene therapies, and small molecules administered through oral or intravenous routes.
• Promising emerging therapies in development include Niraparib, an oral PARP inhibitor, and ZEN-3694, which targets BET proteins to inhibit tumor growth.

Download for updates and the latest revolution in Prostate Cancer care @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Prostate Cancer Emerging Drugs Profile

• Niraparib: Janssen Research & Development
Niraparib is an oral PARP inhibitor being developed by Janssen Research & Development. It is designed to target DNA repair mechanisms in cancer cells, particularly those with certain genetic mutations. Currently, it is being evaluated in clinical trials for its efficacy and safety in patients with various stages of prostate cancer, including metastatic castration-resistant prostate cancer.

• ZEN-3694: Zenith Epigenetics
ZEN-3694 is a novel BET inhibitor that targets bromodomain and extra-terminal (BET) proteins to inhibit the expression of genes that drive tumor growth. Developed by Zenith Epigenetics, this small molecule is currently undergoing clinical assessment to determine its ability to overcome resistance to standard androgen receptor-targeted therapies in prostate cancer patients.

• Ladiratuzumab vedotin: Seagen / Merck
Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting LIV-1, conjugated to a potent microtubule-disrupting agent. It is designed to bind to LIV-1 on the surface of cancer cells and deliver the cytotoxic payload directly into the cell. Currently, its potential is being explored in various solid tumors, including prostate cancer.

For more information on the Prostate Cancer Emerging Drugs Profile, download DelveInsight's comprehensive Prostate Cancer Pipeline Insight report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Prostate Cancer Pipeline Report Provides

• Detailed insights about companies developing therapies for Prostate Cancer, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.
• Prostate Cancer companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prostate Cancer drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Prostate Cancer market.

Learn more about Prostate Cancer drug opportunities in our comprehensive Prostate Cancer pipeline report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Prostate Cancer Companies and Competitive Landscape

There are 140+ key companies, including Janssen Research & Development, Pfizer, Astellas Pharma, Regeneron Pharmaceuticals, Merck, AstraZeneca, Novartis, and others, developing therapies for Prostate Cancer, with a significant number of candidates in various stages of clinical development.

DelveInsight's Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Prostate Cancer products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Prostate Cancer treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Prostate Cancer Pipeline Report

• Coverage: Global
• Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Regeneron Pharmaceuticals, and others.
• Prostate Cancer Therapies: Niraparib, ZEN-3694, Ladiratuzumab vedotin, FOR46, and other pipeline candidates.
• Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.